Neurometrix (NURO) Earning Somewhat Favorable News Coverage, Report Shows

Media stories about Neurometrix (NASDAQ:NURO) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurometrix earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave headlines about the medical device company an impact score of 47.5487195535114 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

NURO has been the subject of several recent analyst reports. Zacks Investment Research raised Neurometrix from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. ValuEngine raised Neurometrix from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

Neurometrix (NURO) traded down $0.02 during trading hours on Monday, hitting $1.31. The stock had a trading volume of 98,500 shares, compared to its average volume of 1,229,433. Neurometrix has a 12 month low of $1.20 and a 12 month high of $6.08. The company has a market capitalization of $9.35, a PE ratio of -0.08 and a beta of 0.21.

COPYRIGHT VIOLATION WARNING: “Neurometrix (NURO) Earning Somewhat Favorable News Coverage, Report Shows” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at

About Neurometrix

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Insider Buying and Selling by Quarter for Neurometrix (NASDAQ:NURO)

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with's FREE daily email newsletter.

Leave a Reply